The estimated Net Worth of Donald Notman is at least $2.52 Milion dollars as of 3 February 2024. Mr. Notman owns over 6,212 units of Ocular Therapeutix Inc stock worth over $1,648,805 and over the last 7 years he sold OCUL stock worth over $89,492. In addition, he makes $777,410 as Chief Financial Officer at Ocular Therapeutix Inc.
Sign up
Mr. Notman OCUL stock SEC Form 4 insiders trading
Donald has made over 6 trades of the Ocular Therapeutix Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 6,212 units of OCUL stock worth $30,190 on 3 February 2024.
The largest trade he's ever made was buying 12,500 units of Ocular Therapeutix Inc stock on 14 August 2018 worth over $78,625. On average, Donald trades about 2,780 units every 161 days since 2017. As of 3 February 2024 he still owns at least 195,356 units of Ocular Therapeutix Inc stock.
You can see the complete history of Mr. Notman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Donald Notman biography
Donald D. Notman Jr. serves as Chief Financial Officer of the Company. Mr. Notman previously served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics, Inc., a biopharmaceutical company, from May 2014 until March 2017 and as a consultant from March 2017 to December 2017. Prior to joining Thrasos Therapeutics, he served as Managing Director and Head of Private Capital Markets of Leerink Swann LLC, an investment bank specializing in health care, from 2005 to April 2013. Mr. Notman received a B.A. in Economics from Middlebury College and an M.B.A. from The Tuck School of Business at Dartmouth College.
What is the salary of Donald Notman?
As the Chief Financial Officer of Ocular Therapeutix Inc, the total compensation of Donald Notman at Ocular Therapeutix Inc is $777,410. There are 4 executives at Ocular Therapeutix Inc getting paid more, with Antony Mattessich having the highest compensation of $2,126,150.
How old is Donald Notman?
Donald Notman is 60, he's been the Chief Financial Officer of Ocular Therapeutix Inc since 2019. There are 5 older and 10 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.
What's Donald Notman's mailing address?
Donald's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.
Insiders trading at Ocular Therapeutix Inc
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer a Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
What does Ocular Therapeutix Inc do?
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
What does Ocular Therapeutix Inc's logo look like?
Complete history of Mr. Notman stock trades at Ocular Therapeutix Inc
Ocular Therapeutix Inc executives and stock owners
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include:
-
Antony Mattessich,
President, Chief Executive Officer, Director -
Patricia Kitchen,
Chief Operations Officer -
Antony Mattessich,
Pres, CEO & Director -
Michael Goldstein,
Chief Medical Officer -
Donald Notman,
Chief Financial Officer -
Dr. Michael H. Goldstein M.M., M.D., M.B.A.,
Pres of Ophthalmology & Chief Medical Officer -
Patricia Kitchen,
Chief Operating Officer -
Philip C. Strassburger,
Gen. Counsel -
Leslie Williams,
Independent Director -
Charles Warden,
Independent Chairman of the Board -
Suh Hong Seung,
Independent Director -
Bruce Peacock,
Independent Director -
Richard Lindstrom,
Independent Director -
Jeffrey Heier,
Independent Director -
Christopher Brinzey,
Managing Director -
Christopher White,
Senior Vice President, Head of Business and Corporate Development -
Dr. Rabia Gurses Ozden,
Sr. VP of Clinical Devel. -
Scott Corning,
Sr. VP of Commercial -
Tracy Smith,
VP of HR -
Christopher G. White,
Chief Bus. Officer -
William H. Ransone II,
VP of Global Sales & Marketing -
Dr. Peter K. Jarrett Ph.D.,
Chief Scientific Officer -
Donald Notman Jr.,
Chief Financial Officer -
Jaswinder Chadha,
Director -
Jonathan H. Talamo,
Chief Medical Officer -
Charles Andrew Hurley,
Chief Commercial Officer -
James M Garvey,
Director -
James Fortune,
Chief Operating Officer -
Amarpreet Sawhney,
President and CEO -
William J Oshea,
Director -
Eric Ankerud,
See Remarks -
W Bradford Smith,
CFO and Treasurer -
Pravin Dugel,
See Remarks -
Rabia Gurses Ozden,
Chief Medical Officer -
Daniel M Bollag,
Sr. VP Reg. Affairs & Quality -
Kevin F. Hanley,
Sr. VP Technical Operations -
Management Inc. Opaleye,
-
Venture Management Co. V, L...,
-
Ii, L.P.Ascension Health Ve...,
-
Iv, Llcsv Life Sciences Fun...,
-
Venture Capital Iii, L.P.Ve...,
-
Iv, Llcsv Life Sciences Fun...,
-
Road Llc Summer,
-
Merilee Raines,
Director -
Philip C. Strassburger,
General Counsel -
Sanjay Nayak,
Chief Strategy Officer -
Nadia Waheed,
Chief Medical Officer